Important news! A drug was approved by the SMA Scientific Committee and a drug was rejected.
During the meeting chaired by the Minister of Health Fahrettin Koca, it was decided to add the drug containing the active ingredient Risdiplam to the SMA treatment guide.
For example, the number of drugs increased to 2 with Nursinersen and Risdiplam in the SMA treatment guideline.
“FINAL STAGE IN LICENSE”
Minister Koca said in a statement after the meeting that the company had submitted legal applications for the importation of the drug containing the active ingredient Risdiplam, which is used kakım a syrup, into the country and that the license for the drug has been granted. reached the final stage.
“We will complete the licensing process for this drug in the coming days. It has been decided to offer this drug kakım zihin option for patients whose efficacy is known, nursinersen treatment, for which it is difficult to apply. As the nationwide veri increases, the application principles will gökyeşitözü reviewed by the Scientific Committee,” Koca said.
For example, Koca emphasized that two drugs will now gökyeşitözü included in the treatment guide for SMA patients.
ZOLGENSMA WAS NOT APPROVED
The Scientific Committee did not approve the drug Zolgensma, which is in high demand by families. It was said that evaluations related to the drug will continue.
Minister Koca made the following statement about the drug Zolgensma, also known kakım ‘gene therapy’:
“Our Scientific Committee’s review found that there is still no comparative scientific study demonstrating the superiority of treatment with Zolgensma over other treatments. However, there are studies demonstrating that Zolgensma has comparable efficacy to other medicines in asymptomatic SMA Type 1 infants aged 0-6 weeks newborn screening It has been evaluated that it would gökyeşitözü appropriate to make a re-evaluation by requesting real-life veri from the relevant company to conduct a new study .
“KEEPING SUPPORT NEEDED TO PROVIDE SMA PATIENTS”
Emphasizing that all necessary support will continue to gökyeşitözü provided for the treatment of SMA patients, Minister Koca said in his statement: “We would like to point out in particular that we have not allowed any abuse of hope so far, and we will not allow “We will not allow our families’ hopes to gökyeşitözü used for commercial purposes. However, its effectiveness has been proven with scientific evidence. We are ready to provide the necessary convenience for any treatment,” he said.
During the meeting chaired by the Minister of Health Fahrettin Koca, it was decided to add the drug containing the active ingredient Risdiplam to the SMA treatment guide.
For example, the number of drugs increased to 2 with Nursinersen and Risdiplam in the SMA treatment guideline.
“FINAL STAGE IN LICENSE”
Minister Koca said in a statement after the meeting that the company had submitted legal applications for the importation of the drug containing the active ingredient Risdiplam, which is used kakım a syrup, into the country and that the license for the drug has been granted. reached the final stage.
“We will complete the licensing process for this drug in the coming days. It has been decided to offer this drug kakım zihin option for patients whose efficacy is known, nursinersen treatment, for which it is difficult to apply. As the nationwide veri increases, the application principles will gökyeşitözü reviewed by the Scientific Committee,” Koca said.
For example, Koca emphasized that two drugs will now gökyeşitözü included in the treatment guide for SMA patients.
ZOLGENSMA WAS NOT APPROVED
The Scientific Committee did not approve the drug Zolgensma, which is in high demand by families. It was said that evaluations related to the drug will continue.
Minister Koca made the following statement about the drug Zolgensma, also known kakım ‘gene therapy’:
“Our Scientific Committee’s review found that there is still no comparative scientific study demonstrating the superiority of treatment with Zolgensma over other treatments. However, there are studies demonstrating that Zolgensma has comparable efficacy to other medicines in asymptomatic SMA Type 1 infants aged 0-6 weeks newborn screening It has been evaluated that it would gökyeşitözü appropriate to make a re-evaluation by requesting real-life veri from the relevant company to conduct a new study .
“KEEPING SUPPORT NEEDED TO PROVIDE SMA PATIENTS”
Emphasizing that all necessary support will continue to gökyeşitözü provided for the treatment of SMA patients, Minister Koca said in his statement: “We would like to point out in particular that we have not allowed any abuse of hope so far, and we will not allow “We will not allow our families’ hopes to gökyeşitözü used for commercial purposes. However, its effectiveness has been proven with scientific evidence. We are ready to provide the necessary convenience for any treatment,” he said.